TICKERNERD
Menu
TECHTECHHealthcare · Biotechnology

TECH Stock Forecast: Bio-Techne Corp. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$72
−0.21% on the day

The 13 Wall Street analysts covering Bio-Techne Corp. hold a median 12-month price target of $73 — +0.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 5 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.4B
Ticker Nerd rank
94 / 100
Median analyst target
$73
Analysts covering
13
Revenue$321.2M+1.3% y/y
Operating income$95.0M
Net income$54.6M
Free cash flow$86.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
0.0%
YTD
+23.7%
1Y
+17.6%
From 52W high
−0.2%
From 52W low
+67.7%
$43
$73
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TECH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bio-Techne Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
91
Momentum
89
Volatility
87
Value
84
Quality
77
Accruals
68
Growth
67
Revisions
67
Size
14

Issuance (91): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (67): Analysts have, on balance, been cutting their forecasts.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TECH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26TECHHigh $73Median $73Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
1 Buy12 Hold0 Sell
Low $50Median $73High $73

The green dot is the last close — the median target sits +0.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Wells FargoDowngradeEqual-Weight$62 → $73
9 July 2026RBC CapitalDowngradeSector Perform—
9 July 2026RBC CapitalDowngradeSector Perform$62 → $73
30 June 2026BenchmarkDowngradeHold—
30 June 2026TD CowenDowngradeHold—
29 June 2026CitigroupDowngradeNeutral—
26 June 2026BairdMaintainsNeutral—
26 June 2026Stephens & Co.DowngradeEqual-Weight—
26 June 2026William BlairDowngradeMarket Perform—
11 June 2026Piper SandlerInitiatesNeutral—
15 May 2026RBC CapitalReinstatesOutperform$62
7 May 2026CitigroupMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsIn-Line—
7 May 2026Wells FargoMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Feb 2026Wells FargoMaintainsOverweight—
5 Feb 2026CitigroupMaintainsBuy—
5 Feb 2026Evercore ISI GroupMaintainsIn-Line—
5 Feb 2026StifelMaintainsHold—
5 Feb 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TECH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TECH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Bio-Techne Corp. returned +17.6% against +17.3% for the S&P 500, dividends included.

TECH vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26TECHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TECH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.4%
Analysts raising
2
Analysts cutting
0
Fundamentals

Bio-Techne Corp. (TECH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
62.4×

Cheaper than 11% of US stocks

Price / sales
9.3×

Cheaper than 15% of US stocks

Price / book
5.4×

Cheaper than 18% of US stocks

EV / EBITDA
34.1×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
1.3%

Higher than 30% of US stocks

Earnings growth (YoY)
1.3%

Higher than 38% of US stocks

Gross margin
65.8%

Higher than 79% of US stocks

Operating margin
27.9%

Higher than 86% of US stocks

Net margin
15.0%

Higher than 77% of US stocks

Returns & dividend
Return on equity
9.0%

Higher than 61% of US stocks

Return on assets
6.7%

Higher than 84% of US stocks

Dividend yield
0.4%

Higher than 58% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bio-Techne Corp. (TECH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bio-Techne Corp. has a market value of $11.4B and an enterprise value of $11.4B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 1.3% year on year.

  • Net income over the same four quarters: $181.9M, a 15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $1.15.

  • Free cash flow in the twelve months to 30 June 2026: $263.2M.

  • Bio-Techne Corp. spent $41.7M on share buybacks and $49.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 156.1M.

  • Trailing P/E: 62.4×; forward P/E: 31.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.44%, paying out 28% of earnings.

  • Bio-Techne Corp. employs 3,000 people — $405K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

TECH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECHBio-Techne Corp.$11.4B
94
MDGLMadrigal Pharmaceuticals, Inc.$11.3B
68
BMRNBioMarin Pharmaceutical, Inc.$11.1B
61
IBRXImmunityBio, Inc.$10.9B
54
PCVXVaxcyte, Inc.$10.5B
54
HALOHalozyme Therapeutics, Inc.$12.3B
97
BBIOBridgeBio Pharma, Inc.$12.8B
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bio-Techne Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TECH news & analysis

INCY or TECH: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 30 Sept 2026neutral

Zacks Investment Research published a comparison of Incyte (INCY) and Techne (TECH) aimed at value investors in the Medical - Biomedical and Genetics sector. The article examines which of the two stocks may be more attractive from a value-investing perspective.

Why it matters — The piece places Techne under direct comparison with a peer on valuation criteria, offering TECH watchers insight into how the company is viewed within the value-investing segment.

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

PRNewsWire · 23 Sept 2026neutral

At a Special Meeting of Shareholders held on Sept. 23, 2026, Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne.

Why it matters — Shareholder approval is a key procedural step in the proposed acquisition of Bio-Techne by Merck KGaA, moving the deal forward toward completion.

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

PRNewsWire · 22 Sept 2026positive

Bio-Techne announced the opening of a new Customer Experience Center in Düsseldorf, Germany, a flagship facility providing hands-on access to its technologies, workflows and scientific expertise. The center is designed to support researchers and organizations across the DACH and broader EMEA regions while strengthening collaboration, training and innovation within Europe's life sciences community.

Why it matters — The new European flagship center could help Bio-Techne deepen customer relationships and expand its presence in the DACH and EMEA life sciences markets.

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

Zacks Investment Research · 11 Sept 2026neutral

Zacks reported that Techne (TECH) declined 0.1% in the 30 days since its most recent earnings report. The piece reviews what has happened to the stock since that report and discusses what may lie ahead.

Why it matters — A TECH watcher would care about this update because it tracks the stock's performance following the company's latest quarterly earnings release, offering context on market reaction.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

GlobeNewsWire · 9 Sept 2026neutral

Brodsky & Smith, a law firm, issued a shareholder update reminding investors of its investigations into several companies, including Bio-Techne Corporation (Nasdaq: TECH). The notice invites Bio-Techne shareholders to contact the firm to discuss the investigation, with no cost or financial obligation to participants.

Why it matters — Investors in Bio-Techne may want to be aware that the company is subject to an active shareholder investigation by a law firm.

FAQ

Frequently asked questions about TECH stock

What is the TECH stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Bio-Techne Corp. have a median 12-month price target of $73, with estimates ranging from $50 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECH stock a buy right now?

Of the 13 analysts covering Bio-Techne Corp., 1 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bio-Techne Corp. 94 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECH?

As at 5 Oct 2026, Bio-Techne Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (91 of 100).

Will TECH stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.8% from the last close, and Ticker Nerd's factor model ranks Bio-Techne Corp. 94 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECH stock forecast for 2030?

No analyst covering Bio-Techne Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $73 over the next 12 months.

How has TECH stock performed over the past year?

Bio-Techne Corp. returned +17.6% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bio-Techne Corp. do?

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications.

What is the latest news on TECH?

The most recent item we track (Zacks Investment Research, 30 Sept 2026): "INCY or TECH: Which Is the Better Value Stock Right Now?". Zacks Investment Research published a comparison of Incyte (INCY) and Techne (TECH) aimed at value investors in the Medical - Biomedical and Genetics sector. The article examines which of the two stocks may be more attractive from a value-investing perspective.

Company

About Bio-Techne Corp.

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.

CEO Mr. Kim Kelderman · 3,000 employees · United States · https://www.bio-techne.com